Alec Stranahan
BofA Securities, Research Division

My name is Alec Stranahan. I'm a senior biotech analyst here at Bank of America covering CG Oncology. And thanks for joining us for the session with CG and for joining the 2026 BofA Healthcare Conference. I'm pleased to be joined by Arthur Kuan, the Chairman and Chief Executive Officer of CG; and Ambaw Bellete, President and Chief Operating Officer. Thanks for being here, guys.

Arthur Kuan
Chairman & CEO

Thank you.

Ambaw Bellete
President & COO

Thanks for having us.

Alec Stranahan
BofA Securities, Research Division

Yes. Great. Well, maybe just to tee up the conversation, Arthur, you guys had an update with your 1Q last week. Maybe you can just sort of run through at a high level sort of what was new from that and sort of what investors should be paying attention to over the next few months?

Arthur Kuan
Chairman & CEO

Sure. So as many of you know, we've initiated our rolling BLA submission for our first indication last year. And this year, we're basically committing to complete the BLA submission by the fourth quarter of this year. And this is in the BCG-unresponsive high-risk NIBC space. So that's one of the key highlights of narrowing that guidance.

And the second update, the guidance remains the same that we anticipate that in the first half of this year, our top line data from the PIVOT-006 trial could potentially be available. We do continue to emphasize that it is an event-based trial. So it's always hard to pinpoint exactly when that